News
ARGX
358.90
+0.14%
0.49
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 9h ago
Analysts’ Top Healthcare Picks: Elevance Health (ELV), Argenx Se (ARGX)
TipRanks · 15h ago
Jefferies urges deeper dive into mid-caps, picks 12 ideas including GTA-publisher Take-Two
Jefferies urges deeper dive into mid-caps, picks 12 ideas including GTA-publisher Take-Two. Jefferies says large-cap money managers should bulk up their holdings of mid-cap stocks. Mid-caps have not been able to keep pace with the larger stocks, says Jefferies.
Seeking Alpha · 1d ago
Maintaining the Edge: Argenx’s Hold Rating Amidst Rising Competition and Promising Therapy Results
TipRanks · 1d ago
The Analyst Verdict: argenx In The Eyes Of 12 Experts
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. 12 analysts have published ratings on argenx (NASDAQ:ARGX) in the last three months. The company has an average 12-month price target of $463.0. Argenx has an impressive revenue growth rate of 133.6%.
Benzinga · 1d ago
argenx Price Target Maintained With a $521.00/Share by Wedbush
Dow Jones · 1d ago
Wedbush Reiterates Outperform on argenx, Maintains $521 Price Target
Benzinga · 1d ago
HC Wainwright & Co. Reiterates Buy on argenx, Maintains $451 Price Target
Benzinga · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)
TipRanks · 1d ago
argenx SE Becomes Oversold (ARGX)
NASDAQ · 2d ago
Argenx’s VYVGART Shows Promising CIDP Treatment Results
TipRanks · 3d ago
argenx Data Shows Evidence That VYVGART And VYVGART Hytrulo Deliver Transformative Results For Patients Suffering From Debilitating Autoimmune Diseases
Benzinga · 3d ago
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Barchart · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
TipRanks · 4d ago
Weekly Report: what happened at ARGX last week (0408-0412)?
Weekly Report · 4d ago
Argenx Se (ARGX) Receives a Buy from Bank of America Securities
TipRanks · 04/12 13:36
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Needham initiated coverage on Cartesian Therapeutics Inc (NASDAQ:RNAC) in November. The private company is developing re-dosable mRNA CAR-Ts for autoimmune disease. Needham says Descartes-08, a CAR-T therapy designed for treating myasthenia gravis, could achieve peak sales of $4.3 billion.
Benzinga · 04/10 18:34
Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Halozyme's ENHANZE technology drives growth, with Q4 2023 revenue up 27% YoY, projecting $915-$985 million in 2024. Key revenue from royalties, notably Darzalex Faspro, with a healthy financial state. Future growth fueled by subcutaneous versions of blockbuster drugs like Opdivo, Ocrevus, and Vyvgart.
Seeking Alpha · 04/10 10:50
Weekly Report: what happened at ARGX last week (0401-0405)?
Weekly Report · 04/08 09:08
Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Immunovant's IMVT-1402 shows promise for at-home autoimmune treatment. Phase 1 data indicate significant IgG reductions without major side effects. The anti-FcRn antibody can be administered subcutaneously, at home, on a weekly basis. Financial health appears strong with a 40-month cash runway. The company's stock has outperformed over the past year.
Seeking Alpha · 04/04 06:12
More
Webull provides a variety of real-time ARGX stock news. You can receive the latest news about Argenx Se through multiple platforms. This information may help you make smarter investment decisions.
About ARGX
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.